Isoalloxazine (e.g., Riboflavins, Vitamin B2, Etc.) Patents (Class 514/251)
  • Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
    Publication number: 20040063712
    Abstract: Disclosed are pyrrolopyridazine compounds, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.
    Type: Application
    Filed: March 25, 2003
    Publication date: April 1, 2004
    Inventors: Mark Salvati, Stephanie A. Barbosa, Zhong Chen, John T. Hunt
  • Pharmaceutical or dietetic preparation for improvement of fertility and sperm quality
    Publication number: 20040058014
    Abstract: Compositions for improving the fertility of and/or for improving the quality of semen produced by, a male mammal including a reduced folic acid, at least 13 mg zinc, and vitamin B12.
    Type: Application
    Filed: May 15, 2003
    Publication date: March 25, 2004
    Applicant: N.V. NUTRICIA
    Inventors: Regine Patricia Maria Steegers-Theunissen, Robert Johan Joseph Hageman, Arie Nieuwenhuizen
  • Method of dietary supplementation
    Publication number: 20040058012
    Abstract: The present invention relates to a method of supplementing the dietary needs of women whereby an effective amount of a life stage appropriate dietary supplement is administered to a woman at each of her life stages throughout her life.
    Type: Application
    Filed: September 11, 2003
    Publication date: March 25, 2004
    Inventors: Sherry D. Jackson, Jeffrey B. Blumberg
  • Lipid conjugated anti-cancer drugs and methods of use thereof
    Publication number: 20040052837
    Abstract: Lipid based anti-proliferative agents and methods of use thereof are disclosed.
    Type: Application
    Filed: June 24, 2003
    Publication date: March 18, 2004
    Inventors: William Stillwell, Mustapha Zerouga, Laura J. Jenski
  • Combination therapy using a TNF binding protein for treating TNF-mediated diseases
    Publication number: 20040047863
    Abstract: The invention relates to methods for treating or preventing acute and/or chronic arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of a TNF binding protein and methotrexate (N-[4-[[2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid). In a-preferred embodiment, the TNF binding protein is sTNFR-I or sTNFR-II. The invention also relates to pharmaceutical compositions containing a TNF binding protein and methotrexate useful in such methods.
    Type: Application
    Filed: July 16, 2003
    Publication date: March 11, 2004
    Applicant: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello, Carl K. Edwards
  • Combination therapy using a TNF binding protein for treating TNF-mediated diseases
    Publication number: 20040048799
    Abstract: The invention relates to methods for treating or preventing acute and/or chronic arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of a TNF binding protein and methotrexate (N-[4-[[2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid). In a preferred embodiment, the TNF binding protein is sTNFR-I or sTNFR-II. The invention also relates to pharmaceutical compositions containing a TNF binding protein and methotrexate useful in such methods.
    Type: Application
    Filed: July 16, 2003
    Publication date: March 11, 2004
    Applicant: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello, Carl K. Edwards
  • Use of high dose intravenous methotrexate, with leucovorin rescue, to treat early multiple sclerosis and other diseases of the central nervous system
    Publication number: 20040048871
    Abstract: The present invention is directed to a method for treating a non-infectious non-neoplastic inflammatory condition of the CNS comprising administering an initial dose of methotrexate to a human host exhibiting a symptom of said condition at a level which is sufficient to cross the blood brain barrier, wherein said human host has not been clinically diagnosed with said condition, or has not been treated with an immunomodulatory agent. The high dose methotrexate treatment is followed by rescue of the periphery with a methotrexate inhibitor that does not cross the blood brain barrier, and administration of a follow-up treatment considered to have therapeutic value for treating said condition.
    Type: Application
    Filed: September 9, 2002
    Publication date: March 11, 2004
    Inventor: Vernon D. Rowe
  • Compositions and methods for coating medical implants
    Publication number: 20040043052
    Abstract: Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.
    Type: Application
    Filed: May 27, 2003
    Publication date: March 4, 2004
    Applicant: Angiotech Pharmaceuticals, Inc.
    Inventors: William L. Hunter, David M. Gravett, Philip M. Toleikis, Richard T. Liggins, Troy A. E. Loss
  • Use of II-1 inhibitors for treating II-1 mediated diseases
    Publication number: 20040044001
    Abstract: The invention relates to methods for treating or preventing arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of an IL-1 inhibitor and methotrexate. In a preferred embodiment, the IL-1 inhibitor is human recombinant IL-1ra and the methotrexate is N-[4-[(2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid. The invention also relates to pharmaceutical compositions containing an IL-1 inhibitor and methotrexate useful in such methods.
    Type: Application
    Filed: July 16, 2003
    Publication date: March 4, 2004
    Applicant: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello
  • 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors
    Publication number: 20040043984
    Abstract: This invention provides compounds defined by Formula I 1
    Type: Application
    Filed: August 5, 2003
    Publication date: March 4, 2004
    Inventor: Patrick Michael O'Brien
  • Metabolic uncoupling therapy
    Publication number: 20040043013
    Abstract: A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy comprises: analyzing a specific physiologic process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron flux; and formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain.
    Type: Application
    Filed: June 17, 2003
    Publication date: March 4, 2004
    Inventor: Edward Larry McCleary
  • Vitamin/nutrient dosage regimentation
    Patent number: 6696083
    Abstract: The efficacy of vitamins and other nutritional agents in treating and preventing various disease states is improved by administering therapeutically effective levels of these agents on a substantially continuous, 24-hour basis. The concentration of lipid peroxides formed by the autoxidation of lipids, and the concentration of oxygen free radicals, are reduced by continuously administering antioxidant agents. The regeneration of nerve tissue is improved by continuously administering at least one pharmaceutically-acceptable B complex vitamin.
    Type: Grant
    Filed: January 30, 1998
    Date of Patent: February 24, 2004
    Assignee: DrugTech Corporation
    Inventors: George N. Paradissis, R. Saul Levinson, Mitchell I. Kirschner, Marc S. Hermelin
  • Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
    Publication number: 20040034030
    Abstract: The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs.
    Type: Application
    Filed: July 30, 2003
    Publication date: February 19, 2004
    Applicant: ChronoRX LLC
    Inventors: Kenneth T. Richardson, Don C. Pearson
  • Methods for contemporaneous administration of levamisole and 5-fluorouracil
    Publication number: 20040033271
    Abstract: The invention provides an improved method for potentiating the antineoplastic activity of 5-fluorouracil with levamisole, or with an analogue thereof. Specifically, the invention provides regimens wherein levamisole is administered contemporaneously with the administration of 5-fluorouracil, thereby increasing the exposure of tumor tissue to the simultaneous presence of the two drugs. The invention further provides methods for the parenteral administration of levamisole, thereby overcoming the disadvantages associated with inter-patient variability in the bioavailability of oral.
    Type: Application
    Filed: May 30, 2003
    Publication date: February 19, 2004
    Inventor: Seth Lederman
  • Composition and method for altering levels of or sensitivity to adenosine with a dehydroepiandrosterone
    Publication number: 20040034029
    Abstract: A method of treating adenosine depletion in a subject in need of such treatment is disclosed. The method comprises administering to the subject folinic acid or a pharmaceutically acceptable salt thereof in an amount effective to treat adenosine depletion. A method of treating asthma in a subject in need of such treatment is also disclosed. The method comprises administering to the subject dehydroepiandrosterone, analogs thereof, or pharmaceutically acceptable salts thereof in an amount effective to treat asthma.
    Type: Application
    Filed: April 9, 2003
    Publication date: February 19, 2004
    Inventor: Jonathan W. Nyce
  • Compositions and methods for lowering plasma lipoprotein(A) and risk factors of cardiovascular diseases
    Patent number: 6693129
    Abstract: The present invention provides compositions and methods for lowering plasma Lp(a) levels in humans. The present invention provides compositions and methods for lowering the risk factors for cardiovascular diseases. Moreover, this invention provides therapeutic alternatives to current pharmaceutical interventions for the lowering of cholesterol, LDL-cholesterol, triglycerides and other metabolic risk factors.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: February 17, 2004
    Inventor: Matthias Rath
  • Compositions and methods for treating cancer
    Publication number: 20040029815
    Abstract: Methods and compositions are provided for the treatment of cancer that take advantage of the increased uptake of glucose-anti-neoplastic agent conjugates in cancer cells relative to normal cells.
    Type: Application
    Filed: March 28, 2003
    Publication date: February 12, 2004
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: George Tidmarsh, Mark Matteucci, Photon Rao
  • New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
    Publication number: 20040029885
    Abstract: The present invention relates to new dihydropteridinones of the formula (I) 1
    Type: Application
    Filed: August 23, 2002
    Publication date: February 12, 2004
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Eckhart Bauer, Steffen Breitfelder, Christian Eickmeier, Matthias Grauert, Matthias Hoffmann, Thorsten Lehmann-Lintz, Gerald Pohl, Jens Quant, Norbert Redemann, Gisela Schnapp, Martin Steegmaier
  • Food supplement with a slimming effect
    Publication number: 20040028668
    Abstract: A food supplement with a “slimming” effect is disclosed which strengthens the skeletal muscle, protecting the cardio-vascular apparatus of the user, and has as its characterising components propionyl L-carnitine, coenzyme Q10 nicotinamide, riboflavin and pantothenic acid.
    Type: Application
    Filed: July 1, 2003
    Publication date: February 12, 2004
    Inventor: Franco Gaetani
  • Medicaments for treating dementia
    Publication number: 20040024048
    Abstract: The invention relates to the use of &agr;-lipoic acid in reduced or oxidized form or derivatives thereof with intact dithiolane structure in the form of enantiomers or pharmaceutically acceptable salts, amides, esters, thioesters, ethers or metabolites for the adjuvant therapy of dementias.
    Type: Application
    Filed: May 20, 2003
    Publication date: February 5, 2004
    Inventors: Klaus Wessel, Gerald Munch, Klaus Hager, Marlene Kenklies, Michael Lobisch, Manfred Peukert, Harald Borbe, Andreas Marahrens
  • Blood lipid ameliorant composition
    Publication number: 20040023919
    Abstract: A blood lipid ameliorating composition containing atorvastatin in combination with one or more members selected from a riboflavin derivative, a tocopherol compound, an ascorbic acid derivative, pantethine and taurine.
    Type: Application
    Filed: June 11, 2003
    Publication date: February 5, 2004
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Tsuneki Ohsawa, Ikuo Takagi, Ippei Shimizu, Tatsuhito Kondo, Masato Nakayama, Yasuhiro Torizumi
  • Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
    Publication number: 20040022787
    Abstract: The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs).
    Type: Application
    Filed: April 18, 2003
    Publication date: February 5, 2004
    Inventors: Robert Cohen, Suzette Carr, David Hagerty, Robert J. Peach, Jean-Claude Becker
  • Compositions and methods for treating diabetes
    Publication number: 20040023885
    Abstract: Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided.
    Type: Application
    Filed: June 9, 2003
    Publication date: February 5, 2004
    Inventors: Stephen J. Brand, Antonio Cruz
  • Cardiovascular health enhancement with soy fortified orange juice compositions
    Publication number: 20040022877
    Abstract: A method is provided for administering to an individual a soy fortified orange juice composition which includes soy protein that readily dissolves in orange juice and does not unacceptably negatively impact sensory, mouth feel and viscosity attributes of the orange juice component. When administered daily, these compositions enhance cardiovascular health indicators in the individual. The cardiovascular health indicators include cholesterol levels and blood pressure readings for the individual so treated.
    Type: Application
    Filed: July 30, 2002
    Publication date: February 5, 2004
    Inventors: Nancy Green, Richard N. McArdle, Carla McGill, Renee Mellican, Kristin Parshall
  • Cardiovascular health enhancement with soy fortified citrus juice compositions
    Publication number: 20040022876
    Abstract: A method is provided for administering to an individual a soy fortified citrus juice composition which includes soy protein that readily dissolves in citrus juice and does not unacceptably negatively impact sensory, mouth feel and viscosity attributes of the citrus juice component. When administered daily, these compositions enhance cardiovascular health indicators in the individual. The cardiovascular health indicators include cholesterol levels and blood pressure readings for the individual so treated.
    Type: Application
    Filed: July 30, 2002
    Publication date: February 5, 2004
    Inventors: Nancy Green, Richard N. McArdle, Carla McGill, Renee Mellican, Kristin Parshall
  • Composition containing statins and calcium for improved cardiovascular health
    Publication number: 20040018248
    Abstract: The invention provides a composition for oral administration comprising a mixture of a statin, docosahexaenoic acid “DHA”, vitamin E, vitamin C, vitamin B6, vitamin B12, folic acid, and calcium together with a suitable carrier. These compositions are particularly useful as dietary supplements administered to reduce the risk factors of cardiovascular disease, such as elevated serum cholesterol levels and high blood pressure.
    Type: Application
    Filed: May 29, 2003
    Publication date: January 29, 2004
    Inventor: Adrianne Bendich
  • Substituted quinazolinone compounds
    Publication number: 20040019049
    Abstract: A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure IA, IB, or IC where the values of the variable are defined herein.
    Type: Application
    Filed: May 23, 2003
    Publication date: January 29, 2004
    Applicant: CHIRON CORPORATION
    Inventors: Rustum S. Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith
  • Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
    Publication number: 20040019055
    Abstract: The invention provides a combination, comprising an allosteric alkyne inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric alkyne inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib.
    Type: Application
    Filed: July 15, 2003
    Publication date: January 29, 2004
    Inventor: William Howard Roark
  • Dietary supplements
    Publication number: 20040013743
    Abstract: The present invention relates to dietary supplements containing low doses of phytoestrogens for supplementing the specific phytochemical dietary needs of perimenopausal and menopausal women.
    Type: Application
    Filed: June 23, 2003
    Publication date: January 22, 2004
    Inventor: Sherry D. Jackson
  • Antitumour compositions containing taxane derivatives
    Publication number: 20040013660
    Abstract: Antitumor combinations comprising a taxane and at least one therapeutically useful substance for treating neoplastic diseases are described.
    Type: Application
    Filed: April 25, 2003
    Publication date: January 22, 2004
    Applicant: Aventis Pharma S.A.
    Inventor: Marie-Christine Bissery
  • Use of anti-TNFalpha antibodies and another drug
    Publication number: 20040009172
    Abstract: The present invention is directed to a method of treating disorders in which TFN&agr; activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &agr; (hTNF&agr;) in combination with another drug which is useful for treating the disorder. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing are also encompassed by the invention.
    Type: Application
    Filed: April 24, 2003
    Publication date: January 15, 2004
    Inventors: Steven Fischkoff, Elliot Chartash
  • Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
    Publication number: 20040009958
    Abstract: A method of inhibiting the hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of 1&agr;,24(S)-dihydroxyvitamin D2. The method also includes the co-administration of cyotoxic agents with the 1&agr;,24(S)-dihydroxyvitamin D2.
    Type: Application
    Filed: March 18, 2003
    Publication date: January 15, 2004
    Applicant: Bone Care International, Inc.
    Inventors: Charles W. Bishop, Joyce C. Knutson, Stephen Strugnell, Richard B. Mazess
  • Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers
    Publication number: 20040006042
    Abstract: The present invention provides compounds of Formula II: 1
    Type: Application
    Filed: May 28, 2003
    Publication date: January 8, 2004
    Inventors: David Allen Berry, Ellen Myra Dobrusin, Judith Lynne Johnson-Philipsen, Wayne Daniel Klohs, Dennis Joseph McNamara, Leslie Morton Werbel
  • Healthy bone formulation
    Publication number: 20040005366
    Abstract: The key to the unique formulation is a combination of specific vitamins, minerals, herbs and nutrients. These essential components in the amounts provided uniquely contribute to improved blood sugar levels and insulin delivery to the cells. The formulation contains essential amounts of Calcium, magnesium Vitamin D, Vitamin K-1, Folic Acid and Soy Isoflavones, as well as other ingredients and healthy filler components.
    Type: Application
    Filed: July 3, 2002
    Publication date: January 8, 2004
    Inventor: Wayne F. Gorsek
  • Method of treating cancer using FPT inhibitors and antineoplastic agents
    Publication number: 20040006087
    Abstract: Disclosed is a method of treating cancer in a patient in need of such treatment comprising administering a therapeutically effective amount of an FPT inhibitor and therapeutically effective amounts of one or more antineoplastic agents. Methods of treating non small cell lung cancer, squamous cell cancer of the head and neck, CML, AML, non-Hodgkin's lymphoma and multiple myeloma are disclosed.
    Type: Application
    Filed: December 3, 2002
    Publication date: January 8, 2004
    Applicant: Schering Corporation
    Inventors: David L. Cutler, Charles Baum, Sara L. Zaknoen
  • Dietary supplement compositions
    Publication number: 20040005311
    Abstract: The invention is directed to dietary supplements including a core of lysine and bromelain and, optionally, including lycopene. Supplements can further include at least one of Vitamin C, Vitamin E, Vitamin B12, CoEnzymeQ10, lycopene, folic acid, selenium, lecithin and quercetin. Supplements can also further include lutein or xanthin. A preferred supplement includes 5000 mg lysine, 125 mg bromelain, 250 mg Vitamin C,800 IU Vitamin E, 500 mcg Vitamin B 12, 200 mg CoEnzymeQ10, 10 mg lycopene, 800 mcg folic acid, 100 mcg selenium, 250 mg quercetin and 2400 mg lecithin. The supplements have dietary uses or can be used to alleviate dementia-related symptoms.
    Type: Application
    Filed: June 16, 2003
    Publication date: January 8, 2004
    Inventor: Bradford D. Pitman
  • Method for treating inflammation
    Publication number: 20040005320
    Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
    Type: Application
    Filed: April 28, 2003
    Publication date: January 8, 2004
    Inventors: Penny Thompson, Donald C. Foster, Wenfeng Xu, Karen L. Madden, James D. Kelly, Cindy A. Sprecher, Hal Blumberg, Maribeth A. Eagan, Stephen R. Jaspers, Yasmin A. Chandrasekher, Julia E. Novak
  • Synergistic effects of nuclear transcription factor NF-kappaB inhibitors and anti-neoplastic agents
    Publication number: 20040002499
    Abstract: The present invention provides methods of inhibiting metastasis of a tumor and methods of treating a tumor using a combination of an inhibitor of the activation of nuclear factor NF-&kgr;B and a cancer chemotherapeutic agent. In one embodiment of the present invention, combination of curcumin and paclitaxel (taxol) can be used to treat and inhibit metastasis of breast tumor.
    Type: Application
    Filed: April 24, 2003
    Publication date: January 1, 2004
    Inventor: Bharat Aggarwal
  • Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
    Publication number: 20040001899
    Abstract: A method for prevention and treatment of multiple sclerosis and other demyelinating conditions is disclosed. The method includes two subsequent phases. In each phase, a patient orally administers daily a regimen which includes a specific combination of amino acids, fatty acids, vitamins and minerals. The particular regimens provide vital nutrients necessary to re-build fatty acids that may have been lost or reduced in the myelin sheathing and other locations of brain, therefore decrease one's susceptibility to multiple sclerosis and prevent reoccurrence of the disease.
    Type: Application
    Filed: March 12, 2003
    Publication date: January 1, 2004
    Inventor: Duane Bennett
  • Immunosuppressive effects of pteridine derivatives
    Publication number: 20030236255
    Abstract: Novel poly-substituted pteridinediones (lumazines), and mono- or polysubstituted 2-thiolumazines, 4-thiolumazines or 2,4-dithiolumazines, having disclosed substituents in positions 1, 3, 6 and 7 of the pteridine ring, and pharmaceutically acceptable salts thereof, are useful as biologically active ingredients in preparing pharmaceutical compositions especially for the treatment or prevention of a CNS disorder, a cell proliferative disorder, a viral infection, an immune or auto-immune disorder or a transplant rejection. Combinations of the pteridine derivatives of the invention with an immunosuppressant or immunomodulator drug, an antineoplastic drug or an antiviral agent, providing potential synergistic effects, are also disclosed.
    Type: Application
    Filed: May 23, 2003
    Publication date: December 25, 2003
    Inventors: Mark Jozef Albert Waer, Piet Andre Maurits Maria Herdewijn, Wolfgang Eugen Pfleiderer
  • Biocidal methods and compositions
    Publication number: 20030232040
    Abstract: Methods, compositions, and kits for reducing a microbial population on a surface are provided. The microbial populations which can be treated using the methods, compositions, and kits of the present invention include prokaryotic, viral, and protozoan populations. The methods, compositions, and kits of the present invention have a number of uses in the fields of food production and medicine.
    Type: Application
    Filed: June 17, 2003
    Publication date: December 18, 2003
    Applicant: SureCide Technologies, LLC
    Inventors: Kenneth Beckman, John L. Grimsich, Christopher Hawk, Frank Swenson, David Tyler
  • Prophylactic or therapeutic agents for diseases associated with dysfunction of NOS
    Publication number: 20030232835
    Abstract: It is an object of the present invention to provide a therapeutic agent for effectively preventing or ameliorating diseases caused by dysfunction of NOS.
    Type: Application
    Filed: April 8, 2003
    Publication date: December 18, 2003
    Inventors: Takafumi Ishihara, Yoshiharu Kanayama, Mikio Okamura, Junichi Yoshikawa, Haruo Shintaku
  • Small molecules useful for the treatment of inflammatory disease
    Publication number: 20030232817
    Abstract: Compounds of the formula I 1
    Type: Application
    Filed: February 24, 2003
    Publication date: December 18, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventor: Roman Wolfgang Fleck
  • Method of treating interleukin-6-mediated inflammatory diseases
    Publication number: 20030229030
    Abstract: The invention is a method of treating IL-6-mediated inflammatory diseases with flavonoid inhibitors of the production and secretion of IL-6 from human or animal mast or macrophage cells. The most effective flavonoid compounds include quercetin, kaempferol, myricetin and genistein, and these can be administered alone or in combination with S-adenosylmethionine, folic acid, interleukin-10 or a histamine-1 receptor antagonist such as azelastine.
    Type: Application
    Filed: June 11, 2002
    Publication date: December 11, 2003
    Inventor: Theoharis C. Theoharides
  • Cross-linkable phosphonate-containing supramolecular complexes and their use for delivery of therapeutic and diagnostic agents
    Publication number: 20030224038
    Abstract: Cross-linkable, phosphonate containing supramoleuclar aggregates are disclosed, which may be used to advantage, for example, as drug delivery vehicles for the treatment of bone-related disorders.
    Type: Application
    Filed: February 20, 2003
    Publication date: December 4, 2003
    Inventors: Catherine J. Page, Marcus Helfrich
  • Liposome preparation
    Publication number: 20030224037
    Abstract: The present invention provides a liposome preparation containing oxaliplatin and derivatized with a hydrophilic polymer, as well as a pharmaceutical composition for treatment of tumor comprising the liposome preparation. The liposome preparation according to the present invention is characterized in that it is derivatized with a ligand. The ligand is preferably transferrin. In accordance with the invention, the uptake of a pharmaceutical agent in the liposome into tumor cells can be enhanced through transferrin receptors expressed on the surface of the tumor cells.
    Type: Application
    Filed: October 11, 2002
    Publication date: December 4, 2003
    Applicant: Mebiopharm Co., Ltd.
    Inventors: Masazumi Eriguchi, Hironobu Yanagie, Kazuo Maruyama, Tadashi Fujisawa
  • Non-liquid vitamin compositions
    Publication number: 20030225030
    Abstract: A method for orally administering vitamin preparations is described which combine vitamin B12 (B12, cobalamin) and folic acid (folate), with and without pyridoxine (B6), for preventing and treating elevated serum homocysteine (HC), cystathionine (CT), methylmalonic acid (MMA), or 2-methylcitric acid (2-MCA) levels. These metabolites have been shown to be indicative of B12 and/or folic acid deficiencies. Further, it is likely that a B6 deficiency may be present with a B12 or folate deficiency. The method of the invention is also for use in lowering serum HC, CT, MMA, or 2-MCA in patients with or at risk for neuropsychiatric, vascular, renal or hematologic diseases. The method of the present invention eliminates the costly and time consuming steps of distinguishing between vitamin deficiencies once a deficiency is found by measurement of serum metabolite levels.
    Type: Application
    Filed: December 4, 2002
    Publication date: December 4, 2003
    Inventors: Robert H. Allen, Sally P. Stabler
  • Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
    Publication number: 20030223960
    Abstract: The invention relates to a method of treating multiple sclerosis by the use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide in combination with another compound, which is effective in the treatment of multiple sclerosis.
    Type: Application
    Filed: April 15, 2003
    Publication date: December 4, 2003
    Inventor: Joseph Wettstein
  • Anti-acne compositions and methods of use
    Publication number: 20030224064
    Abstract: The present invention relates to a composition for the treatment of acne comprising chlorine dioxide or chlorine dioxide generating compounds as acne reduction agents. The invention also relates to a method for treating acne by topically administering one of the compositions in an amount therapeutically effective to reduce the redness and blemishes associated with acne.
    Type: Application
    Filed: April 24, 2003
    Publication date: December 4, 2003
    Inventor: William O. Kling
  • Use of interleukin-19 to treat cervical cancer
    Publication number: 20030219379
    Abstract: The present invention relates to the anti-cancer activity of IL-19 polypeptide molecules. IL-19 is a cytokine involved in inflammatory processes and human disease. The present invention includes Use of IL-19 for decreasing proliferation of cervical cancer cells, treating cervical cancer, amongst other uses disclosed. IL-19 polypeptides can be administered alone, or can be fused to cytotoxic moieties, and can be administered in conjunction with radiation or chemotherapeutic agents.
    Type: Application
    Filed: April 8, 2003
    Publication date: November 27, 2003
    Inventors: Yasmin A. Chandrasekher, Patricia A. McKernan